BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests - 2The Way to Monetary Health: Individual budget Change
- 3How a seabird native to Hawaii has adapted to life in Honolulu's concrete jungle
- 4The most effective method to Make a Dazzling Site in 5 Basic Advances
- 5Ancient Pompeii construction site reveals the process for creating Roman concrete
- Why do people have baby teeth and adult teeth?
- Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- 10 Demonstrated Systems to Develop Your Internet based Business
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- 1,000-mile Saharan dust storm, from the sky and from the ground
- What to know about voluntary chocolate recall
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Great DSLR Cameras for Photography Devotees
- Where America’s CO2 emissions come from – what you need to know, in charts
